ERYTECH Pharma develops innovative cancer therapies that work by starving tumors.
Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs : a Phase IIb study in Acute Myeloid Leukemia (AML) , a Phase II study in pancreas cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with TEVA.
ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings
ERYTECH Pharma reports cash balance and revenues for the first quarter of 2015
ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the program without modification
ERYTECH Pharma has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index
ERYTECH participe au 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) which takes place in Chicago, Il, USA from May 29 to June 2, 2015 and makes a poster and an oral presentation
ERYTECH Pharma participates in Boston CEO Conference on May 26 and 27, 2015 in Boston, MA, USA
Erytech Pharma attends Bioequity Europe 2015 on May 19 and 20, 2015 in Vienna, Austria and makes a presentation on May 19 at 5 pm.
ERYTECH Pharma makes an oral presentation on April 30 Session 12 from 2:30 pm to 3:30 pm at CITIM 2015 congress which takes place from April 27 to 30 in Ljubljana, Slovenia.